estimated revenue glp-1 drugs Novo cuts prices 70%, but semaglutide could grow in 2026 GLP-1 Drugs Market Size to

The metabolic improvements associated with GLP-1 agonist therapyincluding weight loss, improved glycaemic control, and potential benefits in MASLD (formerly known as non-alcoholic fatty liver disease)could address multiple health concerns simultaneously, though effects specifically in alcohol-related liver disease are not established

The author or authors do not own shares in any securities mentioned in this article

Weight loss drug coverage is moving from wish list to reality for eligible Medicare beneficiaries

pharmaceutical costs have felt out of control

S., et al., Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes: Potential Importance of Selectivity Over Dipeptidyl Peptidases 8 and 9, Diabetes 54, no

In new data from the ATTAIN-2 trial presented at ObesityWeek, researchers revealed the oral GLP-1 also induced similar benefits for adults with overweight or obesity and type 2 diabetes